KerrKG,SnellingAM, 2009.Pseudomonas aeruginosa: a formidable and ever-present adversary,J Hosp Infec 73 338 -44
OkamotoK,GotohN,NishinoT., 2001.Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay,Antimicrob Agents Chemother 45 1964 -71
AloushV,Navon-VeneziaS,Seigman-IgraY,CabiliS,CarmeliY, 2006.Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact,Antimicrob Agents Chemother 50 43 -8
MagiorakosAP,SrinivasanA,CareyRB,CarmeliY,FalagasME,GiskeCG, 2011.Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance,Clin Microbiol Infect 18 268 -81
AminNE,GiskeCG,JalalShah,KeijserB,KronvallG,WretlindB, 2005.Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates,APMIS 113 187 -96
Papp-WallaceKM,EndimianiA,TaracilaMA,BonomoRA, 2011.Carbapenems: past, present and future,Antimicrob Agents Chemother 55 4943 -60
Alvarez-LermaF,GrauS,FerrándezO, 2009.Characteristics of doripenem: a new broad-spectrum antibiotic,Drug Des Devel Ther 3 173 -90
PillarCM,TorresMK,BrownNP,ShahD,Sahm DF, 2008.In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States,Antimicrob Agents Chemother 52 4388 -99
PatersonDL,DepestelDD, 2009.,Clin Infect Dis 49 291 -8
HenryDA,SpeertDP,WarnockDW,CarrollKC,FunkeG, 2011.,Manual of clinical microbiology 677 -80
2013.Clinical and Laboratory Standard Institute (CLSI). Performance standard for antimicrobial susceptibility testing; twenty-third informational supplement M100-S23, 27 14 -8
2015.,2015 [Cited -
PatelJB,TenoverFC,TurnidgeJD,JorgensenJH,WarnockDW,CarrollKC,FunkeG, 2011.Susceptibility testing methods: dilution and disk diffusion methods,Manual of clinical microbiology 1126 -7
HirschEB,TamVH, 2010.Impact of multi-drug resistant Pseudomonas aeruginosa infection on patient outcomes,Expert Rev Pharmacoecon Outcomes Res 10 441 -51
SattiL,AbbasiS,QumarTA,KhanMS,ZA.,R J, 2011.In vitro efficacy of cefepime against multi-drug resistant Pseudomonas aeruginosa: An alarming situation in our setup, 1 12 -6
ParmarH,DholakiaA,VasavadaD,SinghalaH., 2013.The current status of antibiotic sensitivity of Pseudomonas aeruginosa isolated from various clinical samples,Int J Res Med 2 1 -6
NadeemSG,QasmiSA,AfaqueF,SaleemM,HakimST, 2009.Comparison of in vitro susceptibility of clinical isolates of Pseudomonas aeruginosa in a local hospital setting in Karachi, Pakistan,BJMP 2 35 -9
SomilyAM,AbsarMM,ArshadMZ,Al-AskaAI,ShakoorZA,FataniAJ, 2012.Antimicrobial susceptibility patterns of multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin and tigecycline,Saudi Med J 33 750 -55
DrzewieckiA,BulandaM,TalagaK,SodoA,AdamskiP, 2012.Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Entero-bacteriaceae, Pseudomonas and Acinetobacter in Southern Poland,Polskiprzeglad Chirurgiczny 84 449 -53
LeblebiciogluH,CakirN,CelenM,KurtH,BarisH,LaefurrJ, 2012.Comparative activity of carbapenem testing (the COMPACT study) in Turkey,BMC Infect Dis 12 2334 -42
LeeH,KoKS,SongJH,PeckKR, 2011.Antimicrobial activity of doripenem and other carbapenems against Gram-negative pathogens from Korea,Microb Drug Resist 17 37 -45
GimenoC,CantónR,GarcíaA,GobernadoM, 2010.Comparative activity of doripenem, meropenem and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study,Rev Esp Quimioter 23 144 -52
GoldsteinJC,CitronDM,MerriamCV,WarrenYA,TyrrellKL,FernandezHT, 2008.In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds,Antimicrob Agents Chemother 52 761 -6
LouieA,BiedA,FregeauC,ScoyBV,BrownD,LiuW, 2010.Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance,Antimicrob Agents Chemother 54 2638 -45
SahmD., 2012.In vitro activity of doripenem,Clin Infect Dis 49 11 -6
GreerND, 2008.Doripenem (Doribax): the newest addition to the carbapenems,Proc Bayl Univ Med Cent 21 337 -41